Studying the effect of Coenzyme Q10 tablets on the incidence of contrast- associated acute kidney injury in patients undergoing diagnostic coronary angiography

Start Date01 Sep 2026

Sponsor / Collaborator

Tehran University of Medical Sciences

NCT07748130

/ Not yet recruitingNot ApplicableIIT

The Effect of Coenzyme Q10 on Quantitative Changes in Hepatic Fat in Patients With Mitochondrial Diabetes

Mitochondrial diabetes mellitus (MDM) is a rare subtype of diabetes caused by mitochondrial dysfunction, often accompanied by hepatic steatosis. Coenzyme Q10 (CoQ10), a key electron carrier and antioxidant, may improve mitochondrial function and lipid metabolism. This prospective study aims to evaluate the effect of 12-week CoQ10 supplementation (300 mg/day) on liver fat content (assessed by FibroTouch CAP ) in MDM patients with m.3243A>G mutation. An exploratory case-control design will compare baseline characteristics among MDM patients, type 1 diabetes patients, and healthy controls. This study is the first to explore the link between mitochondrial defects and hepatic fat accumulation specifically in MDM, and to test CoQ10 as a potential therapy, offering new insights for both MDM and MAFLD management.

Start Date01 Sep 2026

Sponsor / Collaborator-

CTRI/2026/06/112563

/ Not yet recruitingNot Applicable

Effect of Coenzyme Q10 Supplementation in Trigeminal Neuralgia: A Randomized Controlled Trial - NIL

Start Date15 Jul 2026

Sponsor / Collaborator-

100 Clinical Results associated with Ubidecarenone

100 Translational Medicine associated with Ubidecarenone

100 Patents (Medical) associated with Ubidecarenone

6,296

Literatures (Medical) associated with Ubidecarenone

01 Jan 2027·THERIOGENOLOGY

Mitochondria-targeted antioxidants (MitoQ and Mito-TEMPO) versus untargeted antioxidants (SOD and CoQ10) improve post-thaw quality of rooster sperm by mitigating mitochondrial oxidative damage

Article

Author: Masoudi, Reza ; Nateghi, Reihaneh ; Sharafi, Mohsen ; Barfourooshi, Hoda Javaheri ; Hatami, Maryam

Sperm freezing is a key technique in poultry reproductive technologies, especially for genetic improvement and conservation. Nevertheless, rooster sperm are highly sensitive to freezing-induced damage, resulting in significant declines in sperm quality and fertility. This damage primarily arises from excessive reactive oxygen species (ROS) production, mitochondrial structural disruption, mitochondrial membrane potential loss, lipid peroxidation, and apoptosis pathways activation. This study compared the effects of mitochondria-targeted antioxidants (MitoQ and Mito-TEMPO) and untargeted antioxidants (SOD and CoQ10) on frozen-thawed rooster sperm quality. Semen was diluted with extenders supplemented as follows: control (no antioxidant), SOD (100 IU/mL), CoQ10 (1 μM), MitoQ (50 and 100 nM), Mito-TEMPO (50 and 100 μM), and a combination of MitoQ + Mito-TEMPO (50 nM + 50 μM). Both antioxidant types, especially mitochondria-targeted compounds, significantly improved total and progressive motility, viability, plasma membrane and acrosome integrity, reduced lipid peroxidation, DNA fragmentation, and apoptotic like changes (P ≤ 0.05). The combined MitoQ/Mito-TEMPO treatment showed the greatest protective effects and significantly increased fertility rates compared to control (P ≤ 0.05), indicating enhanced preservation of mitochondrial structure and function. MitoQ reduces electron leakage in the electron transport chain and prevents release of pro-death factors, while Mito-TEMPO scavenges superoxide radicals and maintains mitochondrial redox balance. These results suggest that specific mitochondrial targeting with MitoQ and Mito-TEMPO is an effective strategy to enhance frozen-thawed rooster sperm quality and improve reproductive performance in poultry breeding programs.

01 Dec 2026·JOURNAL OF BIOENERGETICS AND BIOMEMBRANES

Coenzyme Q10 exerts anti-cancer effects in bladder cancer by inducing ROS-mediated apoptosis and autophagy

Article

Author: Zhao, Liping ; Gao, Jingyu ; Wang, Yebo ; Xu, Zhe ; Zhang, Aimin ; Che, Hang ; Wang, Zhao ; Luo, Zijing

Bladder cancer (BCa) is one of the most common types of cancer that impacts the urinary system, and its incidence is increasing worldwide. Coenzyme Q10 (CoQ10) is a naturally occurring fat-soluble quinone with anti-oxidant and anti-inflammatory properties, and it plays a significant role in the suppression of tumor growth. Our objective was to elucidate the potential molecular mechanisms by which CoQ10 affects the advancement of BCa. In our study, human BCa cells 5637 and T24 and normal ureteral epithelial cells SV-Huc-1 were treated with different concentrations of CoQ10. Cell viability, reactive oxygen species (ROS) levels, apoptosis rate, and autophagy levels were assessed by CCK-8 assay, ROS assay kits, flow cytometry, reverse transcription quantitative PCR (RT-qPCR), and western blot analysis. Additionally, xenograft mouse models were conducted to investigate tumor growth. Our data indicated that CoQ10 decreased the viability of 5637 and T24 cells in a concentration- and time-dependent manner, while having minimal impact on SV-Huc-1 cells. Functional experiments uncovered that CoQ10 suppressed cell proliferation, and increased ROS levels, apoptosis, and autophagy in BCa cells. The application of the ROS inhibitor N-Acetyl-L-cysteine (NAC) significantly mitigated these effects. Furthermore, CoQ10 was found to block the Keap1-Nrf2 pathway, whereas the activator of Nrf2 (tert-Butylhydroquinone, TBHQ) and the agonist of HO-1 (Hemin) partially reversed CoQ10-induced ROS accumulation, apoptosis, and autophagy. In the BCa mouse model, CoQ10 inhibited tumor growth, apoptosis, autophagy, and the Keap1-Nrf2 pathway. These findings demonstrated that CoQ10 could be a therapeutic agent for BCa by promoting ROS-mediated apoptosis and autophagy via the Keap1-Nrf2 pathway.

01 Nov 2026·FREE RADICAL BIOLOGY AND MEDICINE

CoQ10 ameliorates intermittent hypoxia-induced ferroptosis by suppressing HMGB1 acetylation and release

Article

Author: Wei, Fan ; Chen, Gongping ; Lin, Ting ; Chen, Jia ; Xie, Hansheng ; Lin, Guofu ; Huang, Jiefeng

Intermittent hypoxia (IH), the core pathological hallmark of obstructive sleep apnea (OSA), elicits long-term cardiac redox imbalance and progressive myocardial dysfunction, yet specific, mechanism-targeted therapies to reverse OSA-associated heart injury remain largely unavailable. This research aimed to systematically unravel the redox-dependent signaling cascade driving IH-induced cardiomyocyte damage and clarify the protective mechanism of coenzyme Q10 (CoQ10), an endogenous antioxidant enriched in cardiac mitochondria. Single-cell RNA-seq profiling identified FAP positive cardiac fibroblasts as the primary cellular source of intermittent hypoxia-induced high-mobility group box 1 (HMGB1), confirming fibroblast-cardiomyocyte paracrine communication as a critical amplifier of myocardial oxidative lesions. In AC16 human cardiomyocytes, IH severely disrupted mitochondrial structure and function, triggering massive reactive oxygen species (ROS) accumulation and excessive lipid peroxidation to initiate ferroptosis, accompanied by suppressed xCT/GPX4/FTH1 and elevated pro-ferroptotic ACSL4. IH also promoted HMGB1 hyperacetylation and subsequent nuclear-to-cytoplasmic translocation to activate the TLR4/NF-κB inflammatory pathway; HMGB1 gene silencing markedly attenuated all IH-triggered pathological phenotypes. Co-IP, ChIP-qPCR and dual-luciferase reporter assays biochemically validated the HMGB1/TLR4/NF-κB/xCT regulatory axis. Consistent findings from in vitro cellular experiments and an in vivo mouse IH model demonstrated that CoQ10 supplementation restores HDAC1/2 expression and enzymatic activity to constrain HMGB1 acetylation, thereby blocking downstream pro-inflammatory and ferroptotic signaling cascades. Collectively, our results confirm that CoQ10 effectively alleviates IH-mediated myocardial oxidative damage by inhibiting HMGB1 release, offering a promising redox-targeted therapeutic candidate for the clinical management of OSA-related cardiovascular complications.

News (Medical) associated with Ubidecarenone

28 Sep 2026

·www.prnewswire.com

DOSE EXPANDS ITS SCIENCE-BACKED APPROACH TO THE CORE SYSTEMS QUIETLY POWERING THE BODY WITH NEW BLOOD PRESSURE LIQUID SUPPLEMENT

The new doctor-formulated, clinically studied liquid supplement combines plant-powered ingredients with finished-formula clinical validation to support healthy blood pressure, blood flow and vascular function* NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Dose today announced the launch of Dose for Blood Pressure™, a doctor-formulated daily liquid supplement designed to support healthy blood pressure, including blood flow, vascular function and circulation. Dose for Blood Pressure is the first liquid supplement [product on the market] to show a statistically significant positive impact on both diastolic and systolic blood pressure in its own double blind, randomized, placebo-controlled clinical study. The launch marks a significant next chapter for Dose, expanding the brand's science-backed approach beyond liver health and cholesterol to another important, and often silent, marker of long-term health.* Continue Reading Dose Blood Pressure Clinical Study Findings Chart Dose is a clinically-backed supplement brand built on the belief that lasting health begins by supporting the body's core systems and the key health markers tied to them, including liver health, cholesterol and now blood pressure. Through liquid formulations that combine recognizable, plant-powered ingredients backed by science, Dose helps consumers take a proactive approach to long-term health with measurable results they can see in their lab work and feel in everyday life.* "From day one, our vision has been to help people take more control of their long-term health by supporting the core systems quietly powering their bodies," said Vasu Goyal, Founder of Dose. "Blood pressure was a natural next step because it's one of the most important, and often misunderstood, health markers. Too many people assume they'll feel when something is changing, when in reality blood pressure can change quietly over time. We saw an opportunity to bring the same rigorous scientific approach that defined our liver and cholesterol formulas to another critical area of long-term health." Blood pressure was a natural next step in Dose's expansion into the core systems and health markers that can meaningfully affect long-term health without producing obvious signs. Like liver health and cholesterol, changes in blood pressure can happen quietly, making it an important area for proactive, consistent support. As Dose's first new product innovation since 2022, Dose for Blood Pressure reflects the brand's highly intentional approach to product development, including 18 months spent refining the formulation through over 100 iterations, and putting it through extensive scientific and clinical testing before bringing it to market. Rather than relying on a single ingredient or pathway, Dose engineered a multi-mechanism formulation combining a proprietary Veldt Grape & Turmeric Blend with science backed CoQ10, grapeseed and folate. Together, the ingredients provide complementary support across healthy blood flow and vascular function, cellular and heart health, antioxidant support and cardiovascular wellness. * Dose also tackled one of the category's key scientific challenges: delivering a clinically backed botanical blend in a stable, absorbable and great-tasting liquid. Using its proprietary formulation and absorption platform, Dose developed the formula in its signature liquid format and went beyond ingredient-level research to clinically evaluate the finished Dose for Blood Pressure formulation, providing clinical validation of the formula as a whole, not just its individual ingredients. In a randomized, double-blind, placebo-controlled clinical study based on 1-2 servings, Dose for Blood Pressure showed a statistically significant and meaningful positive impact in both systolic and diastolic blood pressure.*^ Study findings included: 91% of participants showed a positive impact in systolic blood pressure.1†* 74% of participants showed a positive impact in diastolic blood pressure.1†* 1When taken twice daily ^ Based on a 4-week randomized, double-blind, placebo-controlled clinical study in healthy adults without hypertension per JNC-7/WHO criteria. Percent improvement is based on at least 2 mmHg positive change in systolic or diastolic blood pressure. † Based on a 4-week randomized, double-blind, placebo-controlled clinical study in healthy participants as defined by JNC-7/WHO criteria. Results from Dose for Blood Pressure clinical study complement established approaches like DASH diet and regular exercise.†† ††Results are from separate studies and may not be directly comparable. "Supporting healthy blood pressure isn't about targeting a single ingredient or pathway, it's about supporting an interconnected biological system," said Dr. Jiah Pearson-Leary, Director of Science at Dose. "That's why we designed Dose for Blood Pressure as a multi-mechanism formulation, combining clinically studied ingredients to support healthy blood flow, vascular function and circulation. Just as importantly, we clinically validated the finished formulation, not just the individual ingredients, because consumers deserve confidence in the product they're actually taking every day. * The launch of Dose for Blood Pressure marks the next phase in the evolution of the Dose brand, expanding it from a brand primarily known for liver health into a broader platform supporting the core systems quietly powering the body. Anchored by the brand idea "Healthy Happens Quietly," the evolution reflects a simple truth: consumers can't necessarily feel their liver filtering, cholesterol changing or blood pressure rising, yet these unseen changes can have a meaningful impact on long-term health. Through an expanded portfolio, greater emphasis on clinical research and an evolved brand experience, Dose is helping consumers take proactive daily action before their bodies ask them to. Dose for Blood Pressure joins the brand's existing portfolio supporting liver health and cholesterol, establishing Dose as one cohesive platform helping consumers care for the core systems quietly powering their bodies. Beginning August 31, Dose for Blood Pressure will be available exclusively on dosedaily.co in two sizes: a 16 fl oz bottle (8 servings), available as a three-pack for $90 or six-pack for $160, and a 2 fl oz bottle (1 serving), available individually for $4.99 or as a 24-pack for $99. The formula is vegan, kosher, gluten-free and non-GMO, To learn more about Dose for Blood Pressure and explore Dose's full portfolio, visit dosedaily.co. About Dose Dose is a clinically backed supplement brand creating doctor-formulated liquid supplements that help consumers take a proactive approach to long-term health by supporting the body's core systems. Combining recognizable, plant-powered ingredients with clinical research, each formula is thoughtfully designed with ingredient blends to deliver measurable results consumers can see in their lab work and feel through consistent daily use. * The Dose portfolio includes solutions for liver health, cholesterol and blood pressure, all delivered in a convenient, great-tasting liquid format that simplifies daily supplementation without compromising efficacy. By helping consumers care for the body's core health systems, Dose is making proactive wellness approachable, effective and easy to fit in your daily routine. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Media Contact: [email protected] SOURCE Dose 21% more press release views with Request a Demo

Clinical Result

07 Sep 2026

·www.prnewswire.com

U.S. District Court Invalidates Kaneka's Ubiquinol Patent, Clearing the Way for Cocrystal Tech's CrysQnol™ in the U.S. Market

Judge Overturns Kaneka's '080 Patent for Lack of Utility and Enablement, Removing Legal Uncertainty for Customers and Partners JIAXING, China, Sept. 7, 2026 /PRNewswire/ -- Cocrystal Technology (Jiaxing) Co., Ltd. ("Cocrystal Tech") today announced that the U.S. District Court for the Eastern District of New York has ruled in the company's favor in its long-running patent dispute with Kaneka Corporation, holding that the two patent claims asserted against Cocrystal Tech are invalid. In a Memorandum and Order issued September 2, 2026 in Kaneka Corp. vs. Cocrystal Technology (Jiaxing) Co., Ltd. et al., Case No. 1:23-cv-07483 (E.D.N.Y.), the Court found that Kaneka failed to meet the utility and enablement requirements of U.S. patent law, entered judgment in Cocrystal Tech's favor, and closed the case. As a result, Cocrystal Tech is entitled to continue to manufacture, market, and sell its reduced coenzyme Q10 (ubiquinol) ingredient, marketed under the CrysQnol™ trademark, in the United States without restriction under the invalidated patent. Kaneka filed suit against Cocrystal Tech in October 2023 in the Eastern District of New York, alleging that Crystal QH® - Cocrystal Tech's flagship ubiquinol ingredient, now marketed as CrysQnol™ - infringed U.S. Patent No. 7,829,080 (the "'080 Patent"). The asserted claims cover compositions of reduced coenzyme Q10 containing any amount of reduced coenzyme Q11, a naturally occurring minor component found in CoQ10 materials. Although Cocrystal Tech stipulated that its product fell within the literal language of the asserted claims, it maintained throughout the litigation that the claims were invalid. Following nearly two years of fact and expert discovery, the Court agreed, finding on summary judgment that Kaneka's asserted invention was based on an untested hypothesis rather than a patentable invention. The Court further noted that even Kaneka's own inventors and expert witnesses could not explain, and had never studied, how or why coenzyme Q11 would have any stabilizing effect. The ruling brings welcome finality to a dispute that has spanned nearly three years and removes a significant source of uncertainty for the U.S. nutraceutical industry. With the asserted patent claims invalidated, brand partners, formulators, CMOs and distributors can evaluate CrysQnol™ on its own technical and commercial merits - including stability, bioavailability, formulation flexibility, supply security, and cost efficiency. The decision also underscores years of investment in Cocrystal Tech's proprietary cocrystal stabilization technology, reinforcing the company's position as an innovator in the global ubiquinol ingredient market. "Our focus has never been on following an established path, but on solving difficult scientific problems through our own research and technology," said Dr. Xuefeng Mei, Founder of Cocrystal Tech. "We are pleased that the Court has recognized the importance of the issues at stake in this case. For us, the ruling marks not an endpoint, but an opportunity to bring our technology to more customers and continue innovating in the U.S. market". Introducing CrysQnol ™ : The New Name for Cocrystal's Ubiquinol In conjunction with this legal milestone, Cocrystal Tech - owner of the Crystal QH® trademark - has initiated the transition to its new CrysQnol™ brand, formalizing the rebrand across its global trademark matrix. Customers and partners can expect full continuity of formulation and specifications through the transition, with the CrysQnol™ brand now serving as the unified identity for Cocrystal's ubiquinol ingredient. The favorable ruling comes as Cocrystal Tech continues to expand its portfolio of premium, science-backed nutritional ingredients. Built on the company's proprietary Cocrysta™ technology platform, Cocrystal Tech's ingredient lineup - including CrysQnol™, CurCutine™, Precitein™, and UroRenu™ - is designed to improve the stability, bioavailability, and performance of some of the industry's most in-demand nutraceutical compounds. Cocrystal Tech remains committed to protecting and growing its intellectual property portfolio and to investing in the research that differentiates its ingredients in an increasingly competitive global market. About Cocrystal Tech Cocrystal Tech is the world's first company to apply pharmaceutical-grade cocrystal technology to human nutrition. We are committed to creating higher-value nutrition solutions that deliver more with less. We believe true innovation goes beyond advancing science. For us, it means making nutrition solutions more sustainable, more accessible, and more impactful for people everywhere. Our ingredients and formulations are now trusted across North America, Europe, and Asia-Pacific by leading brands and partners worldwide. For more information, visit . Media Contact: Christina Huang, Marketing Director Cocrystal Technology (Jiaxing) Co., Ltd. [email protected] SOURCE Cocrystal Technology (Jiaxing) Co., Ltd. 21% more press release views with Request a Demo

Patent Infringement

03 Sep 2026

·www.prnewswire.com

KANEKA UBIQUINOL™ WINS NUTRAINGREDIENTS ASIA INGREDIENT OF THE YEAR: HEALTHSPAN AWARD 2026

Award Shines Spotlight on Ubiquinol's Role in Mitochondrial Health and Mitoceutical Innovation in the Global Healthspan MovementSeventh International Accolade Affirms Kaneka Ubiquinol™ Leadership in Evidence-Based Mitochondrial Health, Supporting Healthspan from Preconception to Healthy Ageing[i]The Lancet Public Health, August 2026: Global lifespan–healthspan gap widens to 10.7 years, underscoring the importance of supporting general health and wellbeing throughout life, especially in ageing individuals[ii] BANGKOK, Sept. 3, 2026 /PRNewswire/ -- Kaneka Corporation, the sole global manufacturer of Ubiquinol, is thrilled to announce that Kaneka Ubiquinol™ has been awarded Ingredient of the Year: Healthspan Award at the NutraIngredients-Asia Awards 2026. The highly coveted award represents Kaneka Ubiquinol's third consecutive recognition at the NutraIngredients-Asia Awards, following Healthy Ageing Ingredient of the Year as the Winner in 2024 and the Innovation in Women's Health Award as a Finalist in 2025. Continue Reading Kaneka Ubiquinol™ was named Ingredient of the Year – Healthspan at the NutraIngredients-Asia Awards 2026, spotlighting mitochondrial health and the emerging “mitoceuticals” category. Kaneka Ubiquinol™ wins NutraIngredients-Asia Healthspan Ingredient of the Year. From left: Tingmin Koe, Editor, NutraIngredients-Asia; Kazuki Takita, Assistant Manager, Marketing & Sales (APAC), Kaneka Ubiquinol™; Tsuyoshi Takakuwa, Head of Marketing & Sales APAC, Kaneka Corporation; and Gary Scattergood, Managing Director Asia, William Reed and Publisher, NutraIngredients-Asia. The latest accolade recognises Kaneka Ubiquinol™ at a pivotal time in healthcare, as attention increasingly shifts beyond lifespan – the number of years we live – towards healthspan: maintaining health and wellbeing throughout life. At the heart of this conversation is mitochondrial health. Mitochondria, commonly referred to as the 'powerhouses of the cell', are fundamental to cellular energy production, found in almost every cell in the body[iii]. The endogenous antioxidant Ubiquinol, supports the production of energy in the mitochondria and helps reduce cellular free radical damage[iv]. This growing "mitoceutical" category - nutraceuticals purpose-formulated to support mitochondrial function - is central to advancing healthspan science. Evidence shows that each heart cell contains approximately 5000+ mitochondria,[v] with every cell in the body powered by mitochondria, supporting energy production from preconception to healthy ageing, placing mitochondrial health at the centre of Kaneka's decades-long research into Ubiquinol[vi]. "To receive our seventh international accolade and third consecutive recognition from NutraIngredients-Asia is an extraordinary honour," said Tsuyoshi Takakuwa, Head of Marketing and Sales (APAC), Supplemental Nutrition Business Division, Kaneka Corporation. "We sincerely thank the judges, our customers, research partners, healthcare professionals and our team who continue to advance understanding of Ubiquinol and mitochondrial health worldwide. We also congratulate our fellow finalists and winners." "Our vision extends across the lifespan, supporting healthspan from preconception to general health and wellbeing with ageing. As an innovation partner to brands worldwide, we are committed to combining 50+ years of Ubiquinol research with scientific education, ingredient expertise and collaboration to help advance health solutions globally," said Kazuki Takita, Assistant Manager, Marketing and Sales (APAC), Kaneka Ubiquinol™. Gary Scattergood, Managing Director Asia, William Reed, Publisher of Nutraingredients Asia remarked, "the judges were hugely impressed with the wealth of scientific evidence behind the ingredient, as well as the significant evidence of commercial success across the region, with an impressive line-up of advocates across medical and healthcare practitioners." ABOUT KANEKA UBIQUINOL™ Kaneka Corporation is the sole global manufacturer of clinically researched bioidentical Ubiquinol, produced via an award-winning Japanese natural fermentation process. Backed by 110+ scientific studies, 80+ patents and 50+ years of research, antioxidant-active Ubiquinol supports mitochondrial health, cardiovascular health, cognition, women's health, reproductive health, energy and wellbeing. Listed in 50+ countries in 1,000+ practitioner and OTC nutraceutical brands since 2006. Kaneka Ubiquinol's adherence to the highest manufacturing standards guarantees a stable ingredient, free from impurities, meeting rigorous quality and sustainability requirements — setting the benchmark for production quality via its unique, globally patented yeast fermentation process. Kaneka Ubiquinol™ carries multiple certifications, including HALAL, GRAS, HACCP, NDI, KOSHER, GMP, ISO 14001, ISO 22000, Non-GMO, Non-Animal Origin, and OSHMS. Kaneka Ubiquinol™ is the proud winner of multiple awards: NutraIngredients-Asia Ingredient of the Year: Healthspan Award 2026 Vitafoods Europe Innovation Award 2026 — Most Innovative Consumer-Ready Nutraceutical Finished Product, in partnership with Eqology Pure Arctic Oil Heart & Energy Tmall Global Marketing Innovation Award 2025 Finalist, NutraIngredients-Asia Innovation in Women's Health Award 2025 Natural Health Products New Zealand Forbes Packaging Marketing Award 2025 CMA Raw Material Supplier of the Year Award 2024 NutraIngredients-Asia Healthy Ageing Ingredient of the Year Award 2024 EMAIL: [email protected] WEBSITE: SOURCE Kaneka Ubiquinol™ 21% more press release views with Request a Demo

100 Deals associated with Ubidecarenone

External Link

KEGG	Wiki	ATC	Drug Bank
D01065	Ubidecarenone	C01EB09	DB09270

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	Japan	Eisai Co., Ltd.	27 Jul 1976

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Phase 2	United States	Berg LLC	30 Jan 2022
Squamous Cell Carcinoma	Phase 2	-	BPGbio Inc	01 Mar 2008
Superficial basal cell carcinoma	Phase 2	United States	BPGbio Inc	01 Mar 2008
Multiple System Atrophy	Phase 2	Japan	Nobelpharma Co., Ltd.	-
Glioblastoma	Phase 1	United States	Berg LLC	30 Jan 2022
Brain Cancer	Phase 1	United States	BPGbio Inc	01 Oct 2013
Brain metastases	Phase 1	United States	BPGbio Inc	01 Oct 2013
Colorectal Cancer	Phase 1	United States	BPGbio Inc	01 Oct 2013
Alzheimer Disease	Preclinical	Canada	University of Windsor	19 Jun 2026
Parkinson Disease	Preclinical	Canada	University of Windsor	19 Jun 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06570811 (Pubmed \| BMC Pharmacol Toxicol)	Phase 3	Breast Cancer	60	Paclitaxel + CoQ10	cosawfuqao(zqnahpsusy) = icylsglegg vprtedhsfd (lvbcyotqry ) View more	Positive	04 Jul 2026
				Paclitaxel	cosawfuqao(zqnahpsusy) = netdnfmzkf vprtedhsfd (lvbcyotqry ) View more
AACR2026	Not Applicable	-	47	Reduced coenzyme Q10 (rCoQ10)	mflneiqtgn(lceqzimmny) = While the overall incidence and severity distribution of diarrhea did not significantly differ, a trend toward reduced occurrence of Grade 2 diarrhea was observed in the rCoQ10 group. pclhwtjgnz (yvulxzrtnm ) View more	Negative	21 Apr 2026
				Placebo
NCT05871086 (Pubmed \| Immunopharmacol Immunotoxicol)	Phase 3	Juvenile Idiopathic Arthritis	58	CoQ10 (100 mg/day)	wmipchsacz(cbgtgxhnmr) = qxjkahrdbn dwbkurgnfh (dkxicbeycp ) View more	Positive	15 Apr 2026
				Placebo	wmipchsacz(cbgtgxhnmr) = rvebmeqegv dwbkurgnfh (dkxicbeycp ) View more
NCT06405204 (Pubmed \| Drug Des Devel Ther)	Phase 3	-	100	Coenzyme Q10 + folic acid	aedrdmgrcy(bzbfcmcglg): P-Value = 0.001 View more	Positive	01 Mar 2026
				folic acid
NCT06452134 (Pubmed \| Pain Manag)	Phase 4	-	70	Coenzyme Q10 supplementation	diarjmthbo(geejheznrh) = kgcmmpkmed chfnuajcmx (xtzvktxptz ) View more	Positive	02 Sep 2025
				coenzyme Q10 (Placebo)	pzjqkgjuku(bgeyrmpnhy) = gkpoylwjxf xveuktdhge (agaanpyfls ) View more
NCT02865460 (CTgov)	Phase 3	Fatigue Syndrome, Chronic \| Persian Gulf Syndrome \| Coenzyme Q10 Deficiency	100	Ubiquinol (Ubiquinol)	qortefkqjs(picuoqferp) = edshkpsabp yjwphcnxhp (gbbuvyylze, 11.1) View more	-	15 Feb 2023
				Placebo (Placebo)	qortefkqjs(picuoqferp) = tyidwjegrq yjwphcnxhp (gbbuvyylze, 10.1) View more
EUCTR2020-005961-16-DK \| NCT04960215 (Pubmed)	Phase 2	Post Acute COVID 19 Syndrome	121	Coenzyme Q10 500 mg/day	lnmunnybqw(fdetneuaxb): mean difference = 0.01 (95% CI, -0.02 to 0.04), P-Value = 0.45 View more	Negative	02 Nov 2022
				coenzyme Q10 (Placebo)
NCT03133793 (Pubmed)	Phase 2	Heart failure with normal ejection fraction	216	Placebo ubiquinol capsules and d-ribose powder	cydneddkph(qpwokgfxrw) = bpjvgmemko keycqoxpks (ngfuikifdo ) View more	Positive	01 Aug 2022
				Ubiquinol capsules (600 mg/d) and placebo d-ribose powder	cydneddkph(qpwokgfxrw) = qlfimdsfph keycqoxpks (ngfuikifdo ) View more
NCT03133793 (CTgov)	Phase 2	Heart Failure, Diastolic	216	Placebo powder (Placebo Only)	choxdtiyqo(ilandivugr) = ztxzmktpul vqevubctji (evfbfhkuqh, 24.04) View more	-	03 Mar 2022
				Placebo powder+CoQ10 (CoQ10 Only)	choxdtiyqo(ilandivugr) = dfpsedoumc vqevubctji (evfbfhkuqh, 18.61) View more
NCT02934555 (CTgov)	Phase 2	Post-Cardiac Arrest Syndrome \| Heart Arrest	48	Ensure+Ubiquinol	nagietzrfc(zennugjsje) = kiyzllgmyv cfeocwycon (phbuvmtszi, ggnuyxmhxb - eenzzkrdms) View more	-	15 Feb 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis